TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
In an Oct. 31, 2026, MedPage Today opinion article, South Asian physician Hamayle Saeed describes being screened for diabetes at a BMI of 23 but unable to qualify for a GLP-1 weight-loss drug at a BMI of 26.5 without diabetes. Her account highlights a gap between ethnicity-sensitive clinical guidance and commonly used coverage thresholds; the article’s evidence and policy claims have not been independently verified here.
South Asian physician Hamayle Saeed says she was screened for diabetes under guidance that uses a BMI of 23 for Asian Americans, but was told she did not meet the BMI threshold for a GLP-1 weight-loss drug at 26.5 because she had no diabetes. In an Oct. 31 opinion article for MedPage Today, she describes the mismatch as a gap between ethnicity-sensitive screening and drug eligibility or insurance rules.
Saeed writes that the American Diabetes Association’s guidance prompted diabetes screening because Asian Americans can develop the disease at lower body weights. She says she did not qualify for an FDA-approved GLP-1 under thresholds commonly used for weight management: a BMI of 30, or 27 with a weight-related condition. At 26.5 and without diabetes, she met neither threshold, she says. Her account concerns her own experience; the article does not identify her clinician or insurer.
The article argues that these rules apply different BMI concepts to the same patient. Saeed cites the World Health Organization’s lower action points for Asian populations and a study of nearly 1.5 million adults in England. In that study, she reports, South Asians reached a diabetes-risk level comparable to white adults at BMI 30 at a BMI of 23.9; the corresponding figure for Chinese adults was 26.9. These figures describe risk comparisons in the cited research, not individual diagnoses or automatic drug eligibility.
Saeed also cites a 2025 study of semaglutide in South Korea and Thailand. Participants entered under a local obesity definition beginning at BMI 25. In a post hoc subgroup of 68 participants whose starting BMI was below 30, the 45 assigned semaglutide lost an average of 17.6% of body weight, compared with 4.4% among 23 assigned placebo, according to her account. The subgroup findings do not establish coverage eligibility or show that every patient below BMI 30 would benefit similarly.
How BMI Rules Shape Drug Access
The issue Saeed raises is that screening thresholds and treatment coverage thresholds serve different purposes, but patients can experience the difference as inconsistent care. A lower BMI threshold may prompt clinicians to look for diabetes risk among Asian patients, while a separate drug label, insurer policy or prior authorization form may use higher BMI cutoffs. The practical result, she argues, is that some patients identified as higher-risk may not qualify for a weight-loss prescription unless they develop another qualifying condition.
Coverage restrictions can also affect access beyond an individual case. Saeed says Medi-Cal stopped covering GLP-1 drugs for weight loss in January and MassHealth followed in July. Those dates and policy details are reported in her article; the piece does not provide the full plan rules, exceptions or current eligibility pathways. If coverage narrows, patients near a threshold may face additional barriers, though the scale of that effect is not established in the supplied material.
The broader question is how evidence about body composition and disease risk should inform reimbursement. Saeed cites research suggesting BMI may not reflect body fat distribution equally across populations, alongside trial evidence involving Asian participants. That evidence may inform clinical and policy debates, but it does not by itself settle how insurers should define obesity or which patients should receive a particular medicine.
Products Worth Considering
Withings BPM Connect Wi-Fi and Bluetooth Blood Pressure Monitor
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Oura Ring 5 Smart Ring, Silver, Size 8
As an affiliate, we earn on qualifying purchases.
The Guidelines and Labels Differ
Saeed’s account describes several standards that are often treated as if they were interchangeable. The ADA screening guidance identifies people who may warrant diabetes testing; it does not automatically establish eligibility for medication. BMI cutoffs in drug trials, FDA labeling and insurer authorization policies can also differ. A screening threshold of 23 therefore does not, on its own, require a plan to cover a GLP-1 drug at that BMI.
In the article, Saeed says the 2026 ADA standards call for ethnicity-appropriate cutoffs when assessing excess body fat and specifically refer to South Asian patients. She also says U.S. GLP-1 labels revised in 2026 describe indications using terms such as obesity or overweight with a weight-related condition, while the familiar numerical cutoffs continue to appear in trial criteria and payer forms. The supplied material does not include the full label text or individual insurance policies, so their exact wording and application should be checked directly.
She points to a similar adjustment in guidance from Britain’s National Institute for Health and Care Excellence, which she says lowers BMI thresholds by 2.5 units for several ethnic groups in its tirzepatide recommendations. These examples show that policies can account for population-specific risk in different ways; they do not make the systems directly equivalent.
“The ADA guideline that flags me for annual diabetes screening and the prior authorization form that denies me the drug are describing the same 26.5. Only one of them was written with an Asian body in mind.”
— Hamayle Saeed, MD, in a MedPage Today opinion article
Coverage Rules and Evidence Limits
The source is an opinion article based partly on Saeed’s personal experience, not an independent investigation of her medical or insurance records. It does not name the clinician or payer involved, reproduce a denial notice, or establish whether an appeal or alternative coverage route was available. The article also does not provide a comprehensive review of current insurer policies or exceptions.
The study figures and policy descriptions are reported by Saeed, and the source material supplied here does not include the underlying papers, full FDA labels or plan documents. The 68-person subgroup in STEP 11 was analyzed after the trial, and its results cannot alone determine treatment suitability for other people below BMI 30. It remains unclear how widely insurers use the thresholds Saeed describes, how often ethnicity-specific guidance changes prescribing, and whether or when coverage policies will be revised.
What Could Change Eligibility
The immediate next step for readers seeking a decision about coverage is to consult the current drug label, insurer policy and prior authorization criteria for their specific plan. The article does not announce a new FDA rule, an insurer policy change or a scheduled review that would resolve the discrepancy. Whether professional guidance or emerging trial evidence leads payers to revise their criteria remains open.
Further scrutiny would require checking the cited research and comparing plan rules, including any exceptions or appeals processes, with current clinical guidance. Until that happens, Saeed’s central concern remains a reported gap: an ethnicity-sensitive threshold may prompt diabetes screening well before a patient meets the BMI criteria often used for weight-loss drug coverage.
Key Questions
What happened in this report?
South Asian physician Hamayle Saeed wrote that she was screened for diabetes at a BMI of 26.5 under guidance that uses a lower threshold for Asian Americans, but did not qualify for a GLP-1 weight-loss drug under the BMI criteria she describes.
Does a diabetes screening threshold make someone eligible for a GLP-1?
No. A screening threshold identifies people who may warrant testing; it is not the same as a drug’s indication or an insurer’s coverage rules. Eligibility depends on the applicable label, clinical circumstances and payer policy.
What BMI thresholds does Saeed describe for weight-loss drug eligibility?
She describes commonly used criteria of BMI 30, or BMI 27 with at least one weight-related condition. Actual coverage requirements can vary by drug, insurer and plan, and should be checked against current documents.
What did the semaglutide study show for participants below BMI 30?
Saeed reports that a post hoc subgroup of 68 STEP 11 participants starting below BMI 30 lost an average of 17.6% of body weight with semaglutide, compared with 4.4% with placebo. The subgroup result does not establish an individual treatment recommendation or automatic coverage.
Has a new policy changed access?
The article reports a mismatch between screening guidance and coverage criteria; it does not announce a new FDA or insurer policy. Whether payers will change their rules remains unclear.
Source: medpagetoday.com
